Incyte (INCY) Cash from Operations Growth (3y) (2013 - 2026)
Incyte (INCY) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 34.32% |
| 10 | Incyte | 23.78 Bn | 19.76 Bn | 1.17 Bn | 76.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.49% |
| Dec 31, 2025 | 24.19% |
| Sep 30, 2025 | 23.58% |
| Jun 30, 2025 | -36.43% |
| Mar 31, 2025 | 7.24% |
| Dec 31, 2024 | 48.95% |
| Sep 30, 2024 | 6.81% |
| Jun 30, 2024 | -74.66% |
| Mar 31, 2024 | 2.02% |
| Dec 31, 2023 | 11.24% |
| Sep 30, 2023 | -6.72% |
| Jun 30, 2023 | 4.40% |
| Mar 31, 2023 | 46.34% |
| Dec 31, 2022 | 29.17% |
| Sep 30, 2022 | 3.10% |
| Jun 30, 2022 | 4.42% |
| Mar 31, 2022 | 11.49% |
| Dec 31, 2021 | 11.22% |
| Sep 30, 2021 | 8.60% |
| Jun 30, 2021 | 74.76% |